Long-term safety sits at the center of this dementia and brain health question.

Recent data presented at the AD/PD 2026 conference in Copenhagen reveals that patients treated with LEQEMBI (lecanemab), an FDA-approved Alzheimer’s disease medication, continue therapy at high rates over extended periods—with approximately 67% persisting at two years and maintaining cognitive benefits. This real-world evidence from over 18 months of clinical follow-up shows that despite requiring regular intravenous infusions and MRI monitoring, the treatment is well-tolerated enough that most patients who start it choose to continue.

The data fills a critical gap in our understanding of how anti-amyloid antibodies perform outside controlled clinical trials, where patient adherence, side effect management, and practical implementation challenges often differ substantially from the structured research environment. This article examines what the 2026 long-term safety data tells us about lecanemab’s real-world safety profile, including the types and frequencies of adverse events, the role of genetic risk factors, and how these findings can guide treatment decisions for individuals with early Alzheimer’s disease. We’ll also discuss the practical implications of requiring regular imaging and infusions, and what the sustained cognitive benefits mean for patients considering this treatment option.

How Does Lecanemab Perform in Real-World Treatment Over Two Years?
What Is the Full Safety Profile of Lecanemab Treatment?
Understanding Amyloid-Related Imaging Abnormalities and Genetic Risk Factors
Managing Side Effects and Monitoring Requirements in Clinical Practice
What the Genetic and Demographic Data Reveals About Individual Risk Variability
Four-Year Benefit Data and What It Means for Long-Term Treatment Decisions
What 2026 Safety Data Means for Future Alzheimer’s Treatment Approaches
Conclusion

How Does Lecanemab Perform in Real-World Treatment Over Two Years?

The most striking finding from the 2026 data is the treatment persistence rate tracked through insurance claims and clinical records. Among early Alzheimer’s disease patients in the United States, 78.4% continued lecanemab at 18 months, 71.7% at 20 months, and 67.3% at 24 months. This persistence is notable because it reflects patients making an active choice to continue a treatment that requires monthly or bimonthly visits for intravenous infusions lasting about an hour each. To put this in perspective: in clinical trials of other neurological treatments, persistence often drops below 50% when patients transition from structured research settings to routine care, yet lecanemab shows stronger adherence than many less demanding therapies. The reason patients persist with lecanemab, according to both the real-world data and the Clarity AD trial extension, is that benefits continue to accrue over time.

In the Clarity AD Phase 3 study, 94% of patients who completed 18 months of active treatment enrolled in the long-term open-label extension, indicating confidence in the drug’s value. Patients who remained on lecanemab showed continued cognitive benefits even after four years of treatment compared with the expected natural decline of Alzheimer’s disease—a trajectory that reinforces the decision to continue therapy for those tolerating it well. However, this persistence data masks important variability. Some patients cannot tolerate the treatment and discontinue because of side effects, while others experience logistics challenges or costs that lead to dropout. The data represents patients who made it to the two-year mark, not the full population who initiated treatment; therefore, understanding the safety profile that enables these high persistence rates is essential.

How Does Lecanemab Perform in Real-World Treatment Over Two Years?

What Is the Full Safety Profile of Lecanemab Treatment?

The clinical trial data comparing lecanemab to placebo shows a range of side effects at different frequencies. Infusion-related reactions—fever, chills, or inflammatory symptoms occurring during or shortly after treatment—occur in 26% of lecanemab patients versus 7% receiving placebo. Most infusion reactions are mild to moderate and managed by slowing the infusion rate or pretreatment with antihistamines and corticosteroids. Headaches occur in 11% of lecanemab patients compared to 8% on placebo, while gastrointestinal side effects like nausea and vomiting appear in 6% on the active drug versus 4% on placebo. The adverse events that physicians and patients focus on most intensively relate to brain imaging changes. These amyloid-related imaging abnormalities (ARIA) appear on MRI scans as either microhemorrhages (ARIA-H) or areas of brain edema (ARIA-E). ARIA-E, representing fluid accumulation in brain tissue, occurs in 13% of lecanemab recipients compared to 2% on placebo.

ARIA-H, showing small bleeds from weakened blood vessel walls, appears in 14% of lecanemab patients versus 8% on placebo. Additionally, 6% of lecanemab patients develop superficial siderosis (iron deposits on the brain surface) compared to 3% on placebo. Rash, which can be concerning but is usually manageable with dermatology consultation, occurs in 6% versus 4% on placebo. While these imaging findings sound alarming, the critical distinction is between asymptomatic ARIA and symptomatic ARIA. Most patients with ARIA-E or ARIA-H on their MRI scan have no symptoms—they feel perfectly normal. However, symptomatic ARIA, where the imaging changes cause actual clinical symptoms such as headache, confusion, or balance problems, occurs in only 3% of lecanemab patients. Serious symptomatic ARIA, requiring hospitalization or significant clinical intervention, occurred in 0.7% of trial participants. This distinction—between an MRI finding and a clinical problem—has profound implications for how we approach treatment monitoring.

Amyloid-related imaging abnormalities (ARIA) arise because lecanemab clears amyloid protein that has deposited in blood vessel walls and brain tissue. As the amyloid dissolves, the structures weakened by amyloid accumulation become temporarily more vulnerable, leading to microhemorrhages or edema. Meta-analysis data from anti-amyloid antibody trials shows pooled ARIA-E rates of 25.5% and ARIA-H rates of 17.8%, reflecting that brain imaging changes are common with this class of therapy—not unique to lecanemab. One of the most important discoveries from recent Alzheimer’s research is the role of the APOE ε4 genetic variant in determining ARIA risk. Individuals carrying the APOE ε4 allele have higher genetic risk for amyloid accumulation and Alzheimer’s disease, but they also have substantially higher risk for ARIA when treated.

Among carriers of two copies of APOE ε4 (homozygotes), serious ARIA events occurred in approximately 3% during trials—roughly four times the rate in the general treatment population. Carriers of one APOE ε4 copy have a 5.6-fold higher risk of ARIA-E and 3.45-fold higher risk of ARIA-H compared to non-carriers; when looking at ARIA-E specifically, carriers have a 2.19-fold elevated risk. This genetic stratification has prompted discussions about whether genetic testing should precede lecanemab treatment. If a patient carries APOE ε4 homozygote status, more intensive MRI monitoring, closer clinical follow-up, and potentially more cautious dosing might be warranted—though clinical guidelines on this remain evolving. For patients without APOE ε4 copies, the ARIA risk profile is substantially lower, which influences the risk-benefit calculation. Importantly, when ARIA-E does develop, it is generally transient and resolves when treatment is paused or stopped, and may even self-resolve while treatment continues—a reassuring finding for managing these imaging abnormalities.

Understanding Amyloid-Related Imaging Abnormalities and Genetic Risk Factors

Managing Side Effects and Monitoring Requirements in Clinical Practice

The requirement for monthly or bimonthly intravenous infusions and regular MRI monitoring creates a practical care burden that affects real-world persistence. Every patient on lecanemab needs MRI scans at baseline, after three months, and then at least annually to screen for asymptomatic ARIA. This requires not only the time investment and cost of the scans themselves, but also coordination with imaging centers and neurology clinics. Despite these logistical demands, the 2026 real-world data showed that MRI monitoring requirements and other treatment factors did not substantially affect lecanemab dosing adherence—indicating that patients view the monitoring as an acceptable cost of accessing a disease-modifying treatment. Infusion-related reactions, while common at 26%, are highly manageable in clinical practice through several strategies. Premedication with corticosteroids and antihistamines reduces both the frequency and severity of infusion reactions.

Slowing the infusion rate over the first few months also reduces reactions. Most patients who initially experience infusion reactions tolerate subsequent infusions without significant problems once management strategies are optimized. The key is coordinating with an infusion center experienced with lecanemab and maintaining open communication about any symptoms during or after infusions. However, if a patient develops symptomatic ARIA—particularly symptomatic ARIA-E causing cognitive decline, confusion, or headache—the treatment approach changes significantly. In these cases, lecanemab is typically paused to allow the edema to resolve, and some patients do not resume treatment, while others restart at a lower dose or less frequent schedule after the acute episode resolves. The minority of patients experiencing serious symptomatic ARIA may require hospitalization, and some do not continue long-term therapy. For this reason, the clinical assessment phase in the first months of treatment—when patients are evaluated for both efficacy and tolerability—is critical for identifying who is likely to have a favorable long-term course.

What the Genetic and Demographic Data Reveals About Individual Risk Variability

Not all patients face the same risk when starting lecanemab, and this individualized risk assessment has become central to treatment planning. APOE ε4 status represents the largest known genetic determinant of ARIA risk, but age, baseline cognitive impairment severity, comorbidities like cerebral amyloid angiopathy (a condition where amyloid damages small blood vessels), and prior brain imaging abnormalities also influence outcomes. A patient with early cognitive decline, no APOE ε4 copies, and clean baseline MRI imaging faces substantially lower ARIA risk than a patient with more advanced cognitive impairment, APOE ε4 homozygote status, and evidence of small vessel disease on imaging. The practical implication is that genetic counseling or APOE ε4 testing before initiating lecanemab is increasingly recommended but not yet standard everywhere.

If you or a family member is considering lecanemab treatment, discussing baseline risk factors with the treating neurologist—including genetic status if available, age, and baseline imaging—allows for more informed decision-making about monitoring intensity and treatment goals. Some patients at lower risk might feel confident with annual MRI screening, while others at higher genetic or imaging-based risk might benefit from more frequent monitoring (such as MRI every three to six months during the first year). One limitation of the current safety data is that the real-world cohort may differ from clinical trial participants in unmeasured ways. Patients who enrolled in trials were more closely monitored and perhaps more health-conscious than the general population. The real-world data from insurance claims represents actual practice patterns, but it doesn’t capture all the contextual factors influencing treatment persistence, such as access to imaging, insurance coverage decisions, or patient education quality at different treatment centers.

What the Genetic and Demographic Data Reveals About Individual Risk Variability

Four-Year Benefit Data and What It Means for Long-Term Treatment Decisions

One of the most significant findings supporting continued lecanemab use is that patients maintaining treatment for four years continue to show cognitive benefits compared to the expected natural trajectory of Alzheimer’s disease. This extended benefit window addresses a key uncertainty: whether the disease-modifying effect of lecanemab persists over years or whether the initial benefit wanes over time. The data suggests the former—that patients who tolerate and persist with lecanemab sustain their cognitive advantages across a four-year period.

This sustained benefit profile has reframed how neurologists and patients think about lecanemab’s role in Alzheimer’s management. Rather than a short-term intervention aimed at buying time, lecanemab appears positioned as a long-term disease-modifying therapy for appropriate candidates. The 67% persistence rate at two years, combined with continued benefits in those who persist, suggests that a subset of the Alzheimer’s population will derive meaningful long-term value from the treatment—provided they can tolerate the monitoring, manage side effects, and maintain access to regular infusions.

What 2026 Safety Data Means for Future Alzheimer’s Treatment Approaches

The 2026 safety and persistence data represents the first real-world evidence at meaningful scale and time horizon for lecanemab, and it arrives as other anti-amyloid antibodies (donanemab, remternetug, and others) are advancing toward FDA approval or are already approved. The safety profile from lecanemab—including ARIA frequencies, genetic risk factors, and long-term tolerability—is likely informative for these other monoclonal antibodies, though each drug will ultimately require its own safety characterization. The consistency in ARIA rates across anti-amyloid therapies in clinical trials suggests that ARIA risk is an inherent feature of the amyloid-lowering approach, not unique to one drug.

Looking forward, the field is moving toward more precision medicine in Alzheimer’s treatment selection. Genetic testing for APOE ε4 status, advanced biomarker testing (including amyloid, tau, and phosphorylated tau in blood), and baseline imaging assessment will increasingly inform whether anti-amyloid therapy is recommended for a given patient and at what monitoring intensity. The 2026 persistence and safety data provide the real-world foundation for these individualized treatment decisions, showing that when the risk-benefit equation favors treatment initiation, most patients who start lecanemab continue it and experience sustained cognitive benefits.

Conclusion

The long-term safety and persistence data released in 2026 demonstrates that LEQEMBI (lecanemab) is a well-tolerated disease-modifying treatment for early Alzheimer’s disease in the real-world setting, with approximately two-thirds of patients continuing treatment at two years and sustaining cognitive benefits throughout that period. While amyloid-related imaging abnormalities appear on MRI scans in a subset of patients, symptomatic ARIA requiring clinical intervention is rare, occurring in only 3% of treated individuals.

Individual risk for ARIA and treatment success depends substantially on genetic factors like APOE ε4 status, baseline imaging, and age—information that should inform shared decision-making between patients and their neurologists. If you or a family member has been diagnosed with early Alzheimer’s disease and are considering lecanemab or other anti-amyloid therapies, discussing your individual risk profile, genetic status if available, access to regular infusions and MRI monitoring, and realistic expectations about cognitive benefits will help determine whether this treatment aligns with your clinical situation and personal values. The 2026 data offers reassurance that those who proceed with treatment can expect to maintain both tolerability and cognitive benefits over years—provided appropriate monitoring and side effect management are in place.